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Introduction: requirement for novel molecular 
imaging techniques
Th   e objectives of molecular imaging are the visualization, 
characterization and quantiﬁ   cation of molecular and 
cellular processes non-invasively within intact living 
organisms. Th   is can help evaluate physiological and patho-
physiological processes, facilitate diagnosis and monitor 
the eﬀ   ects of therapy. At the preclinical stage novel 
molecular imaging techniques can facilitate the develop-
ment of new therapies and understanding of novel 
mechanisms of action of biologically targeted agents.
Rheumatoid arthritis (RA) is a chronic systemic in-
ﬂ  ammatory disease, primarily characterised by inﬂ  amed 
synovial tissue in multiple joints leading to localised 
destruction of bone. Despite signiﬁ   cant advances in 
conventional imaging strategies, such as the use of power 
doppler ultrasound scans and magnetic resonance imag-
ing (MRI), the early diagnosis and monitoring of 
inﬂ  ammatory conditions such as RA remains challenging. 
Current imaging reﬂ   ects irreversible pathological and 
anatomical change as opposed to perturbations in 
speciﬁ  c molecular pathways. Pathological change visual-
ized on X-ray imaging may not be seen until many 
months after disease onset [1]. Osteoarthritis (OA) is 
characterised by joint pain, inactivity-related stiﬀ  ness, 
impaired social role and reduced quality of life, which 
may be associated with radiographic abnormalities. It is 
the most prevalent joint disease and a major cause of 
disability [2-4]. While in some ways similar to RA, it is 
recognised that cartilage loss may occur for several years 
before even minor changes can be detected on plain 
radiographs in OA [5]. Molecular in vivo imaging in 
animal models of disease is also important in increasing 
our understanding of disease pathogenesis and in 
developing methods of monitoring disease activity in 
vivo. Robust disease monitoring will also allow for better 
appraisal of potential therapeutics. Ultimately, the aim is 
to translate molecular imaging techniques into functional 
systems for imaging of human diseases such as RA and 
OA.
Imaging modalities and their application to 
musculoskeletal disease
Radionucleotide imaging: the past and the future
Th   e following sections detail how diﬀ  erent radio  nucleo-
tide imaging modalities have been utilized in musculo-
skeletal imaging practice and how they may be further 
deployed.
Radionucleotide techniques have long been established 
for imaging in preclinical animal models as well as in RA 
and related autoimmune conditions. A variety of 
methods have been employed successfully for imaging 
leukocytes with 99mTc,  67Ga and 111In, with particular 
focus on their use in RA, where they remain in routine 
clinical use as diagnostic imaging techniques [6]. Th  e 
oldest radiopharmaceutical proposed for imaging inﬂ  am-
mation was 67Gallium citrate and this remains an estab-
lished technique for imaging pulmonary and musculo-
skeletal inﬂ   ammation, especially in sarcoidosis [7]. A 
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making use of the permeability change that is recognised 
to occur around sites of inﬂ   ammation [8]. Th  ere are 
numerous examples of so-called non-targeted approaches, 
including radiolabelled liposomes, dextran, nanocolloid 
and human immunoglobulin [9-12]. While all these 
techniques have a low cost and are widely available, 
resolution and sensitivity are relatively low. As a further 
example,  99mTc-oxidronate (Tc-HDP) displays abnormal 
uptake over both currently inﬂ  amed  and  chronically 
damaged joints and is very sensitive for the detection of 
joint and subchondral bone abnormalities [13,14], but it 
cannot distinguish accurately between actively and 
chronically inﬂ  amed joints [15].
A radionucleotide can be applied to a speciﬁ  c 
molecular target to improve these issues. mAbs with high 
speciﬁ  city and high aﬃ   nity for their target antigens can 
be utilized for delivery of agents, including radio  nucleo-
tides, enzymes, drugs, or toxins, in vivo. Th  e Fab is a 
region on an antibody that binds to antigens. It is 
composed of one constant and one variable domain of 
each of the heavy and the light chain. Th  is may beneﬁ  t 
both targeting speciﬁ  city, due to decreasing the size of 
labelled conjugate, and may also reduce immunogenicity 
as described below. Scintigraphy utilizing a 99mTc-anti-E-
selectin-Fab has been used with good eﬀ  ect to image 
synovitis in patients with RA, in this case demonstrating 
improved speciﬁ  city compared to a conventional tracer 
for bone and joint (Tc-HDP). Th  is technique demon-
strated particular speciﬁ   city for targeting active joint 
inﬂ   ammation [16]. Th  e absence of signal uptake in 
normal joints by E-selectin targeted imaging described 
above allows for markedly improved detection of active 
joint disease in RA. Th   e mAb described in this study is of 
murine origin, which raises the possibility of host 
immunogenicity. However, the small amounts of mAb 
required for imaging and also the use of the Fab fragment 
devoid of Fc portions, which are thought to be 
responsible for generating host immunity, may reduce 
the likelihood of a human anti-mouse antibody (HAMA) 
response. In this study patients were not tested for a 
HAMA response, but some were imaged again with 
99mTc-anti-E-selectin-Fab 2 to 4 months later with no 
detectable change in the biodistribution of labelled 
antibody. In a previous study of 14 patients with RA that 
received  111In-labelled F(ab’)2 fragment of E-selectin, 
HAMA responses were measured by ELISA comparing 
blood samples taken pre-immunisation and post-
immuni  sation (14 days). No HAMAs were detectable 
following injection.
Other speciﬁ   c molecular targeting techniques have 
been developed but can be aﬀ  ected by the non-speciﬁ  c 
localization of agents to inﬂ  amed tissues. An example 
includes  111I-labelled IL-1 receptor antagonist (IL-1ra), 
which did not show increased localisation compared to 
radiolabelled albumin [17]. It would appear in this study 
that at the doses of labelled IL-1ra used, the most 
substantial eﬀ  ect was for local changes to reﬂ  ect non-
speciﬁ  c  traﬃ     cking of the molecule due to local 
permeability changes in areas of inﬂ  ammation.  Th  e 
therapeutic eﬃ   cacy of IL-1ra (anakinra, which is licensed 
for treatment in RA) requires repeated administration at 
1,000-fold the doses used in the above imaging study. If 
imaging was undertaken with much higher concen  tra-
tions of labelled anakinra, greater speciﬁ   city of signal 
compared to radiolabelled albumin may be achieved; 
however, increasing the dose of imaging agent to that 
level would lead to unacceptable levels of radiation.
Th   e scintographic detection of radiolabelled TNF mAb 
has also been investigated. Twenty-ﬁ  ve percent of the 
99mTc labelled anti-TNF signal could be abrogated 
following prior administration of unlabelled anti-TNF 
[18]. Th   is demonstrates a speciﬁ  c component to imaging, 
but also suggests that 75% of the signal was non-speciﬁ  c 
accumulation of labelled tracer at sites of inﬂ  ammation.
Interestingly, in RA, other workers have demonstrated 
that 99mTc-anti-CD3 scintigraphy can be used to diﬀ  er  en-
tiate between autoimmune rheumatic diseases and 
strongly correlates with clinical ﬁ  ndings for patients with 
RA [19]. More recently it has been demonstrated that 
anti-CD3 therapy is highly eﬀ  ective for the treatment of 
collagen-induced arthritis (CIA), a murine arthritis 
model, with the capacity to generate anti-arthritic CD8+ 
regulatory T cells (Tregs) and expand the relative 
numbers of CD4+ Tregs [20]. Th   is highlights the poten-
tial of how both imaging and therapy could be synergised.
To determine whether overexpression of the high 
aﬃ   nity folate receptor on activated macrophages can be 
utilised to selectively target imaging agents to sites of 
inﬂ   ammation in rats with adjuvant-induced arthritis, 
folic acid was conjugated to a 99mTc chelator and its 
distribution was visualised using gamma scintigraphy in 
healthy rats, rats with adjuvant-induced arthritis and 
arthritic rats that had been depleted of macrophages [21]. 
Uptake was also conﬁ   rmed by pre-administering un-
labelled folate - this demonstrated that the folate imaging 
conjugate concentrated in the extremities of diseased rats 
but not in the extremities of healthy rats. Depletion of 
macrophages also reduced tissue folate receptor content 
with a concomitant reduction in the folate targeted 
signal. Th  is study demonstrates that cell based labelling 
may also be viable for both functional imaging and 
targeted delivery of therapeutics [21].
Positron emission tomography and single photon emission 
tomography
Positron emission tomography (PET) imaging is based on 
imaging emission from isotopes such as 14F and 64Cu. 
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electrons emit λ-rays at 180 degrees to each other. Th  ese 
are detected when they reach a scintillator in the scan-
ning device, creating a burst of light that is detected by 
photomultiplier tubes or silicon avalanche photodiodes.
PET imaging has been applied in in vivo models of 
arthritis. For example, in the K/BxN mouse model of RA, 
the transfer of autoantibodies speciﬁ   c for glucose-6-
phosphate isomerase (GPI) into naïve mice rapidly 
induces joint inﬂ  ammation similar to that seen in RA. 
Th   e autoimmune target for the KRN T-cell and antibody 
response is GPI, which is involved in glycolysis and is 
ubiquitously present within the cytosol and within tissue 
at low levels. More than 50% of humans aﬀ  ected with RA 
have elevated levels of anti-GPI antibodies. In the K/BxN 
mouse model, Wipke and colleagues [22] have shown by 
PET imaging that puriﬁ   ed anti-GPI IgG localizes 
speciﬁ   cally to the front and rear distal joints within 
minutes of intravenous injection, reaches saturation by 
20 minutes and remains localized for at least 24 hours. By 
contrast, control IgG does not localize to joints or cause 
inﬂ  ammation. For this study anti-GPI antibodies were 
labelled with 64Cu and injected into the recipient mice, 
which were then imaged by micro-PET [22]. Th  is work 
has been extended by Binstadt and colleagues [23], who 
have gone on to demonstrate by intravital imaging that 
anti-GPI antibodies caused macromolecular vaso  per-
mea  bility localized to sites destined to develop arthritis. 
Th  ese studies highlight how molecular in vivo imaging 
techniques can be used to dissect the dynamic and organ 
speciﬁ  city of autoimmune attack.
Human studies have also been undertaken. 18F 
ﬂ  uorodeoxyglucose (18F-FDG) PET imaging and methyl-
11C-choline, an isotope of choline that is incorporated 
into cell membranes, can be used to image cellular 
proliferation. Roivainen and colleagues [24] compared 
18F-FDG PET and methyl-11C-choline PET with MRI 
measures of synovial proliferation at the knee in a study 
of ten patients with inﬂ  ammatory arthritis including RA. 
Th   ey found that synovial volumes measured on contrast-
enhanced T1-weighted MRI scans were highly correlated 
with PET measures of membrane turnover and glucose 
metabolism, including the standardized uptake value 
(SUV) for these isotopes (r values of 0.834 for 11C-choline 
and 0.714 for 18F FDG).
Single photon emission computed tomography 
(SPECT) is a nuclear medicine tomographic imaging 
technique that utilizes the emission of gamma rays. 
SPECT imaging is performed by using a gamma camera 
to acquire two-dimensional images from multiple angles. 
Th  is is reconstructed into a three-dimensional dataset, 
similar to those obtained from other tomographic tech-
niques such as MRI, computed tomography (CT), and 
PET. SPECT is similar to PET in its use of radioactive 
tracer material and detection of gamma rays. In contrast 
with PET, however, the tracer used in SPECT emits 
gamma radiation that is measured directly. SPECT scans 
are signiﬁ  cantly less expensive than PET scans, in part 
because they are able to use longer-lived, more easily 
obtained radioisotopes than PET. Th   e widespread use of 
PET is limited by a shortage of centres able to generate 
positron radioisotopes that also have short half lives. 
SPECT uses isotopes that are already in widespread use, 
such as 111In and 99mTc. Rapid advances in SPECT, 
including the use of multiple pinhole collimators, allow 
high-resolution imaging to less than 1 mm. Th  is  enables 
mouse physiology to be quantiﬁ  ed. Th   is has been used to 
good eﬀ  ect in a humanized mouse model of arthritis. 
NanoSPECT/CT co-registration technology has been 
used to image the uptake of 111In labelled anti-E-selectin 
antibody into human synovium that was transplanted 
into SCID mice following graft stimulation with TNFα. 
Th   is demonstrated that activity could be detected in the 
graft at multiple time points following injection with 
clear delineation of the trans  plants in reconstructed 
images with signiﬁ  cant  diﬀ  er  ences  to  111In-labelled 
isotype control antibody [25]. Th   ese results have demon-
strated that this may be a technique with signiﬁ  cant 
promise for small animal imaging. A translational study 
of high resolution SPECT imaging in a murine arthritis 
model and in patients with RA co-registered with MRI 
has also been performed and this is described below.
MRI and high-resolution computed tomography
MRI scanning is the current gold standard modality in 
clinical practice for imaging synovitis and tenosynovitis 
in patients with inﬂ   ammatory arthritis. Studies have 
shown correlations between the degree of inﬂ  ammation 
and the vascularity of synovium obtained at biopsy and 
post-contrast enhancement on matching dynamic MRI 
scans. Scoring systems have been devised that are based 
on quantifying synovial membrane thickening and signal 
intensity on static post-contrast scans. Moderate to high 
reliability has been demonstrated with trained readers 
and quantiﬁ  cation of synovitis in this way is being used 
increasingly as an outcome measure in clinical trials to 
assess response to therapy. MRI-observed synovitis is 
almost invariable in those with active RA, but recent 
studies have also demonstrated its presence in patients in 
clinical remission, emphasizing the sensitivity of this 
technique and the importance of subclinical joint 
inﬂ  ammation [26]. Synovial inﬂ  ammation determined by 
MRI has been shown to be common in OA [27]. However, 
MRI studies are complex and have a new range of 
variables, including diﬀ  erent imaging sequences, proto-
cols and hardware, but quantiﬁ   cation is improving, 
allowing for a good level of accuracy and reliability in 
measurements of cartilage volume and thickness [28]. 
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cartilage thickness change by MRI by detailed mapping 
of changes in cartilage thickness has been developed. 
Th  is demonstrated marked focal changes in cartilage 
thickness over time and correlated with disability [29].
High-resolution delayed gadolinium-enhanced MRI of 
cartilage (dGEMRIC) is an alternative technique that can 
provide further information on the composition and 
structure of the cartilage matrix. Cartilage consists of 
relatively few cells and a hydrated extracellular matrix 
consisting mainly of proteoglycans and collagen, which 
are responsible for load distribution and compressive 
stiﬀ   ness. Proteoglycans consist of numerous glyco  s-
amino  glycan (GAG) side chains that are negatively 
charged, providing the extracellular matrix with the 
majority of its ﬁ  xed charge - this is referred to as the ﬁ  xed 
charge density (FCD). An early feature of OA is the loss 
of GAGs and hence FCD from the tissue; T1 mapping of 
cartilage is performed after intravenous administration of 
gadolinium-based contrast agent, which is able to provide 
an indirect measurement of GAGs, and hence cartilage 
degradation, by detecting changes in the FCD [30-32]. In 
patients with knee pain, GAG depletion as measured by a 
dGEMRIC index has been shown to be predictive of 
development of knee OA in a 6-year follow-up. Th  is 
technique may therefore act as a clinically relevant 
measure of cartilage integrity as well as provide infor-
mation about underlying molecular perturbation [33].
Cartilage quality assessment in small joints may also be 
made using dGEMRIC. An initial study examined four 
patients with OA of the ﬁ   rst carpometacarpal joint, 
demonstrating diﬀ  erences between asymptomatic and OA 
joints [34]. dGEMRIC may also help to assess cartilage 
degeneration in the metarcarpal phalangeal joints of 
patients with RA. A study of 31 metarcarpal joints in 10 
patients with RA demonstrated signiﬁ   cant changes in 
signal from the second and third metarcarpal joints when 
compared to control subjects, whereas measurements of 
cartilage thickness were comparable in both groups [35].
Custom built high-resolution MRI devices have been 
developed to image small joint structures, including the 
bone trabeculae, cartilage, ligaments and tendons [36,37]. 
Th   ese have been developed to generate detailed 
anatomical assessment of the earliest stages of OA [38]. 
Th  is has also added to understanding of the relative 
anatomical diﬀ   erences between OA and changes in 
spondylo  arthritides such as psoriatic arthritis. Advances 
in imaging technology, such as high-resolution 
‘microscopy’ MRI and whole body MRI, and improved 
protocols, such as ultrashort echo time, are expected to 
further delineate pathophysiology [39].
Paramagnetic contrast agents have also been utilised 
for cell tracking studies to monitor T-cell homing in vivo 
after loading T cells with superparamagnetic iron oxide 
(CLIO) nanoparticles conjugated with a peptide sequence 
from the transactivator protein (Tat) of HIV-1. T cells 
were isolated from C57BL/6 (B6) mice and homing of 
T cells to the spleen was demonstrated by MRI following 
their re-injection. A similar technique was also used to 
image T-cell inﬁ  ltrates in the pancreas of diabetic mice 
[40]. Both studies highlight the potential of MRI to track 
cellular events in deep tissues within living animals, 
although this technique may be hampered by the 
minimum number of cells that can be visualised during 
imaging. Ultrasmall superparamagnetic iron oxide 
(USPIO) nanoparticles are an MRI contrast agent that 
consists of an iron oxide core of about 5 nm in diameter 
that is surrounded by dextran, which increases the 
diameter to about 30 to 50 nm. Several USPIO prepara-
tions are in advanced stages of clinical trials, and their 
safety in humans has been increasingly established 
[41,42]. Conjugation of USPIO nanoparticles with ligands 
oﬀ  ers the possibility of MR imaging of molecular targets. 
Reynolds and colleagues [43] have demonstrated that in 
vivo expression of E-selectin during endothelial activation 
in an inﬂ  amed mouse ear model can be depicted with 
MR imaging and that the conjugate did not accumulate in 
non-inﬂ  amed endothelium.
Microfocal CT (micro-CT) is a three-dimensional 
high-resolution CT technique that allows volumetric 
assess  ment at peripheral skeletal sites. It can provide 
accurate depiction of structural changes in arthritides. 
For example, periarticular bone structure in RA patients 
was compared to healthy individuals using this technique 
and demonstrated exact detection of morphologic 
changes of juxtaarticular bone in healthy individuals and 
RA patients [44]. While not directly a functional imaging 
technique, this may hold promise as an anatomical co-
registration modality with other forms of imaging so that 
anatomical and molecular change can be measured 
during the time course of arthritis.
Optical imaging: a viable alternative molecular technique
Optical imaging has already been developed for in vitro 
and ex vivo applications in molecular and cellular biology 
(for example, ﬂ   uorescence confocal microscopy), and 
there are now signiﬁ  cant advances in its development as 
a whole animal in vivo imaging technique, particularly in 
the context of arthritis [45]. Th   e future holds considerable 
promise for non-invasive visualisation of speciﬁ  c 
molecular targets, which as with the other imaging tech-
niques presented here can be synergised with other 
imaging modalities such as CT or MRI. Th  e  development 
of near infrared (NIR) ﬂ   uorophores has also oﬀ  ered 
advan tages  for  in vivo imaging. Signiﬁ  cant  tissue 
autoﬂ   uorescence occurs at lower wavelengths and 
decreases signal sensitivity, whereas this is reduced in the 
NIR range. Hence, NIR in vivo imaging may oﬀ  er  a 
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trast to the other techniques presented, it is compara-
tively low cost, does not require radiation, and multiple 
images can be acquired rapidly. Th  e following sections 
detail how optical imaging may be utilised to visualise 
arthritic conditions in vivo.
Non-specifi  c imaging agents detect permeability change in 
infl  ammatory states
Inﬂ  ammatory arthritides such as RA are characterised by 
vascular inﬂ   ammation and pathologic neoangiogenesis 
[47,48]. Disordered new vessels have increased vascular 
leakiness to macromolecules compared to normal vessels 
[8]. As the vascular permeability increases, this leads to 
plasma extravasation, oedema and swelling. Th  is local 
permeability change has been utilised to explore the non-
speciﬁ  c uptake and deposition of ﬂ  uorescent dye within 
the arthritic joint in vivo. Enhanced localised deposition 
of free dye (not bound to a disease-speciﬁ  c antibody or 
other target) in the arthritic joints of animals with 
induced arthritis have been examined in several studies. 
Th  e NIR ﬂ  uorophore Cy5.5 was visualised in arthritic 
knee joints following induction of antigen-induced 
arthritis in mice [49], and demonstrated an approximately 
1.5-fold increase in signal in arthritic compared to non-
arthritic joints. Two other NIR dyes were evaluated in a 
murine  Borrelia-induced Lyme arthritis model [50]. 
Th   ese techniques rely on the generalised increased blood 
perfusion and ‘vascular leakiness’ that are recognised to 
be present around the inﬂ  amed joint [51]. Th   is may lead 
to as much as a 40-fold increase in macroglobulin perme-
a  bility in the inﬂ  amed joint [8]. A number of diﬀ  erent 
approaches have been deployed to make use of vascular 
permeability change in order to improve the therapeutic 
index of drug treatment. One possibility is the direct 
conjugation of a drug to another larger molecule - an 
example of this is conjugation to polyethylene glycol 
(PEG). Th   is approach has been successfully deployed for 
a number of drugs in routine clinical use, such as the 
PEGylated forms of interferon-α and doxorubicin for the 
treatment of hepatitis C and breast cancer, respectively 
[52]. In RA this approach has demonstrated improved 
localisation to sites of inﬂ   ammation by measuring 
increased levels of ﬂ  uorescence in inﬂ  amed paws with a 
ﬂ   uorescently labelled PEGylated anti-TNFα agent 
compared to a non-PEGylated TNFα inhibitor [53]. Th  e 
pegylated anti-TNFα agent Certolizumab is licensed for 
clinical use in patients with active RA [54].
Targeted imaging agents
Antibody-ligand interactions: determining specifi  city of molecular 
targeting
Speciﬁ  city of dye traﬃ   cking may be enhanced by utilising 
an antibody, or its fragment, directed at a speciﬁ  c 
molecular target. Speciﬁ   c deposition of dye in the 
arthritic joint of antigen-induced arthritic mice has been 
achieved by targeting macrophages with Cy5.5-labelled 
anti-F4/80 antigen. Th   e F4/80 antigen is expressed on the 
macrophages when they accumulate in inﬂ  amed joints 
[55]. Th   ere was, however, a small increase in signal in the 
uninﬂ  amed contralateral knee joints as well as increased 
uptake in inﬂ  amed knee joints with the Cy5.5-labelled 
isotype control antibody. Th   is highlights the challenge of 
identifying speciﬁ  c versus non-speciﬁ  c deposition of dye 
within the inﬂ  amed joint. Optical imaging of arthritis 
utilising a probe directed against folate receptors on 
activated macrophages demonstrated a 2.3-fold increase 
in signal in inﬂ  amed compared to uninﬂ  amed joints [56]. 
Th  is increase was greater than that obtained following 
injection of free dye. Another study has examined in vivo 
ﬂ   uorescent signal returned from allogeneic leukocytes 
that were labelled ex vivo with ﬂ  uorescent dye and re-
injected into arthritic mice [57]. Steroid reduced the signal 
intensity obtained; however, the degree of quantitative 
analysis was hampered by a relatively small change in 
signal intensity compared to the background signal.
In our laboratory, we have demonstrated that 
E-selectin-targeted  in vivo imaging is a quantiﬁ  able 
method of detecting endothelial activation in arthritis 
and can potentially be applied to quantify disease and 
investigate the eﬀ  ects of novel therapies [58]. Figure 1 
demonstrates that E-selectin-speciﬁ   c signal can be 
detected in collagen-induced arthritis, a mouse model of 
RA. Signiﬁ  cant  diﬀ   erences in anti-E-selectin antibody 
NIR ﬂ   uorescent signal can be detected compared to 
signal received from an isotype control antibody. In 
addition, it is also possible to co-register the ﬂ  uorescent 
signal with digital X-rays of the aﬀ   ected area taken 
concurrently. Th  is technique has potential to be trans-
lated into a method of delineating the changes occurring 
to activated endothelium in health and in disease both 
prior to and following therapy.
Activatable imaging agents enable signal amplifi  cation
Ampliﬁ  cation of ﬂ  uorescent signal at the site of inﬂ  am-
mation may be possible by using protease activatable 
probes. Here a cleavable peptide sequence is linked to 
ﬂ  uorescent molecules that are quenched when in close 
proximity to each other, but unquenched following 
cleavage by local proteolytic activity [59]. Th  is may be 
particularly useful for optical imaging of OA, as local 
perturbations in proteolytic activity may be compara-
tively small. Cathepsins have been associated with 
arthritis and bone degeneration [60]. A cathepsin B 
activatable NIR ﬂ  uorescent probe was used in a mouse 
model of OA and showed a three-fold diﬀ  erence in signal 
intensity between normal and osteoarthritic joints 
[61,62]. Th  is particular probe has also been applied to 
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atherosclerotic plaques in vivo [64]. A similar probe was 
used to demonstrate that methotrexate could abrogate 
some of the increased signal found in arthritic joints [65]. 
A further study also demonstrated that speciﬁ  c signal 
could be reduced and correlated with a decrease in 
clinical disease indices such as redness and measurable 
paw swelling [66]. However, these studies did not 
examine whether an uncleavable form of peptide demon-
strated similar signal or whether any speciﬁ  c inhibitor of 
the protease could prevent cleavage in the arthritic joint.
At the preclinical stage a number of diﬀ  erent advances 
in generating either ﬂ   uorescence (for example, GFP 
expression) or light (bioluminescence) have become 
powerful tools to delineate disease pathogenesis over 
multiple time points. Bioluminescence is the conversion 
of chemical energy to light in living organisms, most 
commonly under control of the luciferase enzymatic 
system. Th   ese enzymes convert the luciferin substrate in 
the presence of several co-factors and adenosine 
triphosphate to generate oxyluciferin and light [67]. Th  is 
technology has been most widely used in reporter gene 
assays, where the promoters of genes under study have 
been linked to the luciferase gene, and the resultant light 
is a direct measure of promoter activity. Because the 
luciferase enzyme needs to be transfected into cells or 
expressed in a transgenic line, its use is limited to animal 
models. Pioneering studies have demonstrated in vivo 
imaging of bone forming osteoblasts. Gazit and 
colleagues [68] generated a transgenic mouse model 
containing the luciferase promoter under control of an 
osteoblast-speciﬁ   c osteocalcin promoter fragment. In 
this study, light emission correlated well with the activity 
of osteoblasts in parts of the bony skeleton, matching 
histological expression of osteocalcin expression and 
quanti ﬁ   cation by real time PCR. Furthermore, in two 
skeletal repair models, ﬁ   rstly by bone fracture and 
secondly by marrow ablation, quantitative measurements 
could be made in vivo [68]. Bioluminescence has also 
been used successfully to image and study animal 
arthritis models. Transgenic mice that express luciferase 
under control of the nuclear transcription factor NF-κB 
have enabled real time imaging of NF-κB expression 
during the course of an arthritis model in intact animals 
[69]. Imaging of arthritic joints revealed a strong 
activation of NF-κB on day 6 post-arthritis induction and 
increased expression over the following 4 days. One 
particular advantage bioluminescence has over tradi-
tional ﬂ   uorophores is that tracking can be monitored 
over longer periods (days to weeks) [70].
Image co-registration techniques combine anatomical and 
molecular data
Th  e potential application of molecular imaging tech-
niques is determined by the ability to both quantify 
sensitivity and speciﬁ  city and map this signal to discrete 
tissue structures in vivo. Pre-clinical and clinical multiple 
imaging platforms have been developed, such as PET-CT, 
SPECT-CT or PET-MRI. For example, PET-MRI may 
allow for the analysis of one or more functional processes 
simultaneously along with the delineation of high-
resolution morphology [71]. Hybrid cameras that 
combine SPECT and helical CT can be used to correlate 
scintographic information with morphologic information 
Figure 1. E-selectin-specifi  c signal can be co-registered with plain X-ray imaging in collagen-induced arthritis. Following onset of 
arthritis induced with bovine collagen, mice were injected with either anti-E-selectin or anti-DNP antibodies labelled with Dylight 750 nm near 
infrared fl  uorophore (5 μg intravenously). (a) Data are mean ± standard error of the mean (SEM) of mean fl  uorescence intensity (MFI) for arthritic 
and healthy animals (non-immunised controls), and were analysed by two-way ANOVA versus arthritic anti-E-selectin antibody-injected mice: 
***P < 0.001. (b) Representative image of mouse with hind paw arthritis and corresponding image co-registered with X-ray following subtraction 
of background fl  uorescence. Clinical scores of imaged paws are shown. (c) The corresponding quantifi  cation of MFI at 8 hours for either healthy 
(non-arthritic) animals or mice with clinically defi  nite arthritis and paw thickness ≥2.2 mm. Background fl  uorescence levels from uninfl  amed paws 
have been subtracted. Data are mean ± SEM, and were analysed by one-way ANOVA versus arthritic anti-E-selectin-injected mice: **P < 0.01, 
***P < 0.001. Reproduced with permission from [58].
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Page 6 of 12in one session. Use of SPECT/CT hybrid imaging may 
signiﬁ  cantly increase the diagnostic accuracy of skeletal 
scintigraphy in the staging of malignant disease but it has 
been little used for the interpretation of musculoskeletal 
disorders. A recent pilot study has demonstrated the 
potential beneﬁ   ts of this technique for improving 
diagnostic accuracy in diﬀ   erentiating the aetiology of 
musculoskeletal disorders - among 34 lesions classiﬁ  ed as 
OA on planar and SPECT imaging, 7 were reclassi  ﬁ  ed as 
fracture and one as a benign tumour [72]. Th  is encour-
ages further follow-up work comparing ﬁ  ndings  with 
other imaging modalities such as MRI, clinical outcomes 
and, where possible, histo  pathological correlates.
A combinatorial approach has also been developed for 
optical imaging co-registered to MRI. Concurrent MRI 
and diﬀ   use optical tomography of the breast after 
indocyanine green enhancement has been undertaken 
[73]. Th   is type of technology has developed in conjunc-
tion with suitably constructed probes. For example, 
Olson and colleagues [74] have developed activateable 
cell penetrating peptides linked to nanoparticles to serve 
as dual probes for in vivo ﬂ   uorescence and MRI of 
proteases. Th  is study reports on the use of in vivo 
visualization of matrix metalloproteinase activities by 
MRI and ﬂ   uorescence of dendrimeric nanoparticles 
coated with activateable cell-penetrating peptides that 
have the potential to be labelled with both Cy5 and 
gadolinium. Uptake of such nanoparticles in tumours is 
4- to 15-fold higher than for unconjugated activateable 
cell-penetrating peptides in a mouse tumour model. 
With ﬂ   uorescent molecules, residual tumour and 
metastases as small as 200 μm were detected. In addition, 
once activated, the Gd-labelled nanoparticles deposit 
high levels (30 to 50 μM) of Gd in tumour parenchyma, 
with even higher amounts deposited in regions of 
inﬁ  ltrative tumour, resulting in useful T1 signal contrast 
lasting several days after injection.
Inﬂ   ammatory arthritic lesions have been imaged in 
experimental arthritis and in patients with RA using a 
high-resolution multi-pinhole (MPH)-SPECT technique 
[75]. In the human studies MPH-SPECT images depicted 
a detailed visualization of tracer accumulation in the 
bony structures of the hand and ﬁ   nger joints; these 
studies were also capable of imaging increased bone 
metabolism that had appeared normal with other 
imaging modalities. Th  is is demonstrated in Figure 2. 
Ostendorf and colleagues [76] have also demonstrated 
that MPH-SPECT is sensitive to early changes in RA and 
OA and that the diﬀ   erences between them can be 
detected by diﬀ   erent patterns of uptake. It is also 
interesting to note that this study used a conventional 
tracer, so it is possible that much greater sensitivity could 
be achieved by conjugating the tracer to molecules 
directed at speciﬁ  c molecular targets.
Future perspectives
Conventional and currently clinically available imaging 
strategies for detecting and monitoring arthritis have 
relied mainly on detecting the endpoints of autoimmune 
pathological processes. But molecular imaging now oﬀ  ers 
a new way of detecting and monitoring disease. Develop-
ments in radionucleotide imaging discussed here will 
result in methods of detecting radiolabelled agents 
directed at speciﬁ   c molecular targets. Th  ese have the 
advantage that many of the facilities are already in clinical 
practice. Further developments in software will mean 
that novel co-registration techniques will enable precise 
anatomical localisation of molecular change, but expo-
sure to radiation, especially if multiple imaging points are 
required, may limit routine clinical use. Similarly, MRI 
scanning is in widespread clinical use and the develop-
ment of novel imaging protocols and validation and 
qualiﬁ  cation of their use means that these techniques can 
readily be translated into clinical practice. However, there 
is often heavy clinical demand for current scanning 
equipment and imaging can be time consuming. Further-
more, there may be issues related to the toxicity of 
contrast agents; it is well recognised that gadolinium 
contrast agents may be nephrotoxic [77], and superoxide 
particles may have eﬀ  ects on endothelial cells [78,79]. 
Optical imaging oﬀ   ers a viable alternative imaging 
strategy; images can be obtained rapidly and devices are 
relatively inexpensive. Furthermore, there is no exposure 
to radiation. Developments in ﬂ  uorophore  technology 
have enabled accurate and quantiﬁ  able measurement of 
molecular processes. Th  is technique is also readily 
combined with other imaging strategies.
While it is recognized that joint damage is related to 
disease activity in RA, the degree of progression and the 
temporal associations between the two are unclear [80]. 
However, progression of joint destruction is not always 
directly coupled to the signs and symptoms of RA. 
Following anti-TNFα therapy it has been noted that joint 
disease can be retarded even if active disease is ongoing 
[81,82]. Conversely, there are also reports that joint damage 
can accrue even in states of remission [83,84]. Using 
molecular techniques to sensibly determine sub  clinical 
levels of joint inﬂ   ammation due to the upregu  lation of 
speciﬁ  c molecular pathways may be one way of determining 
levels of disease activity and response to therapy. Th  is  was 
explored in the study by Brown and colleagues [84] where 
the long-term signiﬁ   cance of sub  clinical synovitis was 
assessed in relation to overall structural outcomes. Th  is  was 
performed by analyzing musculo  skeletal ultrasonography 
in addition to MRI scoring measures. Targeted functional 
imaging therefore oﬀ   ers a method of assessing disease 
parameters in a diﬀ  erent way.
Rather than focusing on pathological outcome, changes 
in speciﬁ  c molecular pathways can be measured. Many of 
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targeted approach. Th  ere are several shortcomings of 
mAbs, including their immunogenicity, suboptimal 
target  ing and pharmacokinetic properties, and practical 
issues of production and labelling. Genetic engineering 
provides a powerful approach for redesigning antibodies 
for use in oncologic applications in vivo. Recombinant 
fragments have been produced that retain high aﬃ   nity 
for target antigens, and display a combination of high 
targeting speciﬁ   city with concomitant clearance from 
normal tissues and the circulation in animal models. 
Synovium-speciﬁ  c peptides can also be generated by in 
vivo phage display selection. Th   ese may uniquely hone to 
sites of inﬂ  ammation within the inﬂ  amed synovium [85]. 
Clustering of ﬂ  uorophores onto a larger scaﬀ  old may also 
be used to amplify the ﬂ  uorescent signal.
Aptamer-based technologies and nanoparticles are 
potential novel particles that could be deployed success-
fully for molecular imaging. As oligonucleotide ligands, 
aptamers are comparable to antibodies in speciﬁ  city and 
aﬃ     nity for their target molecule, typically a protein 
[86,87]. At 8 to 15 kDa, aptamers are intermediate in size 
between antibodies (150  kDa) and small peptides 
(15 kDa) and are slightly smaller than sFv (25 kDa). As 
polyanions, aptamers are quite diﬀ  erent in composition 
from sFv. As synthetic molecules, aptamers readily 
support site-speciﬁ  c modiﬁ  cations that maintain struc-
ture and activity. Aptamers can be coupled to diagnostic 
or therapeutic agents and to bioconjugates, such as PEG 
polymers, that can alter aptamer pharmacokinetics. Th  e 
parameters for the in vivo activity of aptamers have been 
investigated in rats with an aptamer directed against 
L-selectin [88]. Previous therapeutic work with aptamers 
has focused on blocking protein function; by far the most 
advanced work is represented by the use of a vascular 
endothelial growth factor aptamer, pegaptanib sodium 
(Macugen; Pﬁ  zer and Eyetech) [89], now approved for 
treatment of macular degeneration [90]. Th  e small size 
Figure   2. Image co-registration in rheumatoid arthritis. Images from a patient with early rheumatoid arthritis, obtained using three diff  erent 
modalities. (a) Conventional radiography. (b) Coronal short tau inversion recovery (STIR) sequence. (d) Axial gadopentate dimeglumine enhanced 
fat-suppressed T1-weighted image. (c,e) Multipinhole single-photon-emission computed tomography (MPH-SPECT) images overlaid with 
appropriate magnetic resonance images (MRI). The overlaid MPH-SPECT images display areas of focally increased bone metabolism in the second 
and third proximal interphalangeal and metacarpalphalangeal joints (corresponding to the boxed area in (a), which showed no bony pathologies 
on MRI. Reproduced with permission from [75].
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blood clearance and tissue uptake and may minimize the 
residence in liver and kidney, providing some potentially 
useful features for imaging and radiotherapy. Initial 
experiments to address aptamer suitability for in vivo 
imaging have been reported [91,92]. Aptamers (small 
oligonucleotide ligands) combined with small particles 
called nanorods made out of gold and silver act as a 
platform to accommodate multiple weak binding reac-
tions. Fluorescently labelled aptamers increase their 
aﬃ   nity for diﬀ  erent cancer cell lines by 26-fold, resulting 
in a 300-fold increase in ﬂ  uorescence signal compared to 
conventional techniques [93]. Th   e use of nanorods in this 
instance may also open potential for therapeutic options. 
Since the nanorods have strong infrared absorption, 
hyperthermia may be generated locally, which could 
speciﬁ  cally ablate tumour or neoangiogenic inﬂ  ammatory 
tissue.
Th   ere are other examples of merging both imaging and 
intervention. In the adjuvant arthritis model of RA, folate 
labelled with ﬂ   uorescein and conjugated with haptens 
(small immunogenic molecules) was used to identify 
activated macrophages and deliver immunotherapy to 
the activated cell population. In these experiments, 
ﬂ   uorescein isothiocyanate (FITC)-labelled folate was 
administered orally to folate-depleted animals and taken 
up preferentially by these cells as a result of their high 
surface expression of a folic acid receptor [21,94]. Th  e 
haptens attached were subsequently expressed on the 
macrophage cell surface, making them highly immuno-
genic. Induction of anti-hapten antibodies in these 
animals via a vaccination schedule resulted in selective 
depletion of activated macrophages, with an anti-inﬂ  am-
ma tory  eﬀ   ect comparable to that achieved by metho-
trexate, etanercept and anakinra in this model. Th  is  kind 
of approach could be used to target a wide variety of cells 
with selectively toxic agents without exposing the patient 
to the risks of non-speciﬁ  c immunosuppression.
GFP from the hydroid jellyﬁ  sh Aequorea victoria and 
GFP mutants and homologues are used intensely in bio-
tech nology.  Th   ey represent the only available ﬂ  uorescent 
tag fully encoded in a single gene. GFP-like proteins are 
utilized for in vivo labelling of organisms, cells, organelles 
and proteins, as well as in molecular sensors that probe 
diﬀ  erent aspects of the intracellular environment. Th  e 
excita  tion and emission spectra of these ﬂ  uorescent 
reporter proteins used thus far for bioluminescence 
imaging has not exceeded 598 nm and 655 nm [95]. Th  is 
signiﬁ   cantly hampers the penetration of excited light 
through tissue and therefore aﬀ   ects the resolution of 
images that may be obtained. More recently, however, 
mammalian expression of infrared ﬂ  uorescent proteins 
has been engineered from a bacterial phytochrome. 
Th   ese higher wavelengths penetrate tissue well and may 
be extremely useful for further in vivo imaging studies 
[96]. Combined with tomographic imaging techniques, 
localisation may be made to precise anatomic sites. Most 
recently a novel multispectral opto-acoustic imaging 
technique has shown signiﬁ   cant potential to image in 
vivo to resolutions of 20 to 100 μm with depth 
penetration that could range up to several centimetres. 
Combining the signiﬁ   cant enhancements in reporter 
proteins suitable for in vivo use and novel hardware 
solutions holds signiﬁ  cant promise [97].
Conclusion
Th   is review has demonstrated that functional molecular 
imaging techniques have the potential to visualise 
pathobiology in a new way. Th   ey can act to delineate the 
mechanism of action of therapy and can also be used to 
monitor therapeutic outcomes in patients with arthritis 
and other inﬂ  ammatory autoimmune conditions, holding 
much promise as future imaging modalities.
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